Alchemia Limited

Lower R&D activities: Alchemia Limited (ASX: ACL) is involved in the operations of developing Oncology Products. In FY 2018, the revenues of the company decreased by 74.7 percent to $8,244. The operating expenses of the company decreased by $191,961 to $380,891, mainly driven by a decrease in research and development activity, which resulted in a decrease in associated corporate costs such as life sciences insurance. The cash reserves of the company decreased by $300,573 to $1,620,290 in FY 2018 and due to the movement in cash the net assets decreased by $372,647 to $1,823,737. In the past six months, the share price of the company decreased by 14 percent as on 17 October 2018. ACL’s shares traded at $0.014 (further down 12.5% on October 18, 2018) with a market capitalization of $5.2 million and thus downtrend might continue in the near term. We believe the stock can be avoided at the current price.

Antisense Therapeutics Limited

Moving on Volatility: Antisense Therapeutics Limited (ASX: ANP) is involved in the operations of discovery and developing of biopharmaceutical drug in Australia; and the group primarily focuses on antisense oligonucleotide products. In FY 2018, the revenue of the company decreased by 81.77 percent to $25,553. The net loss of the company decreased by 15.38 percent to $2.33 million in FY 2018. On 17 October 2018, the shares of the company witnessed an intraday increase of 14.815 percent and the volumes of the shares traded also increased substantially. ANP’s shares traded at $0.062 with a market capitalization of circa $20.07 million as on 17 October 2018. However, the very next day of trading led the stock to fall by about 17.7; and given the volatility, we have a wait and watch view on the stock that trades at the current price of $ 0.051.

Prescient Therapeutics Limited

Strategizing on pipeline products: Prescient Therapeutics Limited (ASX: PTX) is a clinical stage oncology company which is involved in the operations of developing novel compounds for the treatment of a range of cancers in Australia. On 17 October 2018, the company announced that it has initiated a collaboration with a leading private US-based drug development company to develop new formulations of PH domain and Akt inhibitors, building on Prescient’s knowledge gained during its development of PTX-200. Following this news, the share price of the company witnessed an intraday increase of 25% as on 17 October 2018. In FY 2018, the revenue of the company decreased by 24.7 percent to $125,156 as compared to last year. The net loss of the year increased by 0.2% in FY 2018. In the last six months, the share price of the company decreased by 18.18 percent as on 17 October 2018. PTX’s share traded at $0.088 with a market capitalization of $19.07 million and looks speculative while we have a wait and watch view given the collaboration on next generation formulations that it is coming up with.

Medibio Limited 

Net loss widening on year on year basis: Medibio Limited (ASX: MEB) is involved in the operations of developing diagnostic system for mental health illnesses in Australia and the United States. In FY 2018, the total revenue of the company decreased from $3.156 million in FY 2017 to $2.6 million in FY 2018. The net loss of the company increased from $9.785 million in FY 2017 to $16.3 million in FY 2018. On 17 October 2018, the share price of the company witnessed an intraday increase of 27.66 percent as investors tried to punt on low levels.  In the past three months, the shares of the company otherwise decreased by 68.4 percent as on 17 October 2018.MEB’s share traded at $0.055 (down 8.8% on October 18, 2018) with a market capitalization of $12.16 million and is one to avoid till the time key catalysts are noted for the group.  
 
 

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.